• GW4064 and FXR Research: Evidence and Limits

  2026-10-07

  A source-grounded overview of GW4064 as a non-steroidal FXR agonist, its relevance to bile acid and lipid research, findings from a 2024 cholestatic liver injury study, and the limitations that constrain interpretation.

• Fenofibrate, PPARα–YAP Signaling, and Aging Liver

  2026-10-06

  A 2025 study found that Fenofibrate-induced liver enlargement and activation of PPARα-YAP signaling were broadly preserved across adult and aging mouse models. The work strengthens the mechanistic basis for studying age-related hepatic responses to a PPARα agonist, while its mouse-only design limits direct clinical interpretation.

• RNA Clean and Concentrator Kit: Evidence-Ready RNA

  2026-10-06

  The RNA Clean and Concentrator Kit is examined as an evidence-quality tool for RNA purification from enzymatic reactions, not merely a convenience product. This article connects membrane-based cleanup with interpretation of IRES-focused antiviral research while defining the kit’s applicability and evidentiary limits.

• Foretinib Evidence: Five Questions for Better Interpretation

  2026-10-05

  A source-grounded guide to interpreting Foretinib and GSK1363089 evidence, separating kinase mechanism, cancer-response metrics, model-specific findings, and the limits of preclinical translation.

• Fluo-4 AM in Calcium Imaging and Retinal Research

  2026-10-05

  Fluo-4 AM is a fluorescent calcium indicator for tracking relative intracellular Ca2+ dynamics. This overview distinguishes supplier information from primary evidence and examines how calcium imaging could conceptually complement research on a reported ferroelectric-liquid-metal retinal prosthesis, while emphasizing methodological and translational limits.

• GW4064: Evidence, Scope and FXR Signaling

  2026-10-04

  A source-grounded overview of GW4064 as a non-steroidal FXR agonist, examining its biological principle, evidence from a 2025 liver-cell study, interpretation of FXR/TLR4 and ferroptosis findings, and limits on broader translation.

• NAD+ and Cellular Stress: Evidence and Limits

  2026-10-03

  Nicotinamide Adenine Dinucleotide (NAD+) links redox metabolism with enzyme activity and stress signaling, but recent findings on caspase-dependent autophagy do not establish a direct role for NAD+. This overview separates established NAD+ biochemistry from the findings, applications, and limitations of a 2025 study in human breast cancer cells.

• Anlotinib Hydrochloride Assay Workflows

  2026-10-02

  This scenario-based guide explains how Anlotinib hydrochloride, SKU C8688, can improve interpretation and consistency in endothelial migration, tube formation, proliferation, and cytotoxicity assays. It connects reported nanomolar kinase activity with practical experimental design, optimization, comparison, and product-selection decisions.

• Trolox Workflows for Oxidative Stress Assays

  2026-10-01

  Trolox combines practical cell permeability with a defined vitamin E analogue structure, making it useful as both an oxidative stress intervention and a positive control for antioxidant assays. This guide translates its solvent handling, dose design, lipid peroxidation readouts, and disease-model applications into reproducible bench workflows.

• GSK126: Practical EZH2 Inhibitor Workflows

  2026-10-01

  GSK126 connects EZH2 target engagement with H3K27me3 loss, gene reactivation, and cancer-cell state changes. This workflow-focused guide shows how to apply it in lymphoma, EMT, combination-treatment, and broader cancer epigenetics research while avoiding common dosing and solubility errors.

• AO/PI Double Staining Kit: Practical Workflow

  2026-09-30

  The AO/PI Double Staining Kit (SKU K2238) provides a rapid fluorescent cell viability assay that separates viable, apoptotic-like, and membrane-compromised cell populations using Acridine Orange and Propidium Iodide. It is intended for prepared cell suspensions or dispersed cells, not as a standalone method for intact-tissue imaging or definitive assignment of a cell-death pathway.

• CA800-PR Targets Progesterone Signaling in Breast Cancer

  2026-09-30

  The reference study presents CA800-PR, a tumor-targeted heptamethine cyanine dye that combines near-infrared imaging with suppression of progesterone receptor activity in hormone receptor-positive breast cancer models. Its reported effects include Golgi fragmentation, apoptosis, inflammatory signaling, and increased MHC class II-positive, CD80-positive M1-type macrophages, suggesting a treatment concept that connects direct tumor stress with immune remodeling.

• Perospirone: Receptor and Kv1.5 Assay Workflows

  2026-09-29

  Perospirone, also known as SM-9018 free base, supports mechanism-focused schizophrenia research while enabling a parallel investigation of vascular Kv1.5 channel modulation. This practical guide connects receptor pharmacology, patch-clamp experiments, concentration planning, and troubleshooting for neuropsychiatric and cardiovascular assay development.

• GSK-923295 Workflows for Mitotic Precision

  2026-09-29

  GSK-923295 provides a selective way to connect CENP-E motor inhibition with chromosome congression, mitotic arrest, and tumor-cell response. This workflow guide combines dose-response design, live-cell imaging, centromere-focused assays, troubleshooting, and cautious translation to xenograft research.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-28

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that restrains ENO1 activity through acetylation, limits lactate production, and reduces PD-L1 stability in colorectal cancer. Its integrated patient, multi-omics, cellular, and mouse-model evidence suggests that disrupting the NAT1–ENO1–lactate–TRAF6 pathway may improve responses to PD-1 or PD-L1 blockade, while also defining important boundaries for future metabolism-focused experiments.

7841 records 1/523 page Next 12345 下5页 Last page